APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Chemotherapy-Induced Neutropenia Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Chemotherapy-Induced Neutropenia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173977000320 December 2025188 pages

Choose your research edition.

Industry ResearchChemotherapy-Induced Neutropenia Treatment Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Chemotherapy-Induced Neutropenia Treatment Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Chemotherapy-Induced Neutropenia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chemotherapy-Induced Neutropenia Treatment Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Chemotherapy-Induced Neutropenia Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Chemotherapy-Induced Neutropenia Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Chemotherapy-Induced Neutropenia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chemotherapy-Induced Neutropenia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chemotherapy-Induced Neutropenia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Chemotherapy-Induced Neutropenia Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Chemotherapy-Induced Neutropenia Treatment include Teva Pharmaceuticals Industries, Sanofi, Novartis AG, Baxter International, Amgen, Ligand Pharmaceuticals, Dr. Reddy’s Laboratory, Biogenomics Limited and Apotex, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chemotherapy-Induced Neutropenia Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chemotherapy-Induced Neutropenia Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chemotherapy-Induced Neutropenia Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chemotherapy-Induced Neutropenia Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Chemotherapy-Induced Neutropenia Treatment Segment by Company

Teva Pharmaceuticals Industries

Sanofi

Novartis AG

Baxter International

Amgen

Ligand Pharmaceuticals

Dr. Reddy’s Laboratory

Biogenomics Limited

Apotex

Chemotherapy-Induced Neutropenia Treatment Segment by Type

Splenectomy Procedure

Granulocyte Transfusion

Antibiotic Therapy

Colony-Stimulating Factor Therapy

Others

Chemotherapy-Induced Neutropenia Treatment Segment by Application

Ambulatory Surgical Center

Hospitals

Diagnostic Centers

Chemotherapy-Induced Neutropenia Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chemotherapy-Induced Neutropenia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chemotherapy-Induced Neutropenia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chemotherapy-Induced Neutropenia Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chemotherapy-Induced Neutropenia Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chemotherapy-Induced Neutropenia Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Chemotherapy-Induced Neutropenia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Chemotherapy-Induced Neutropenia Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Chemotherapy-Induced Neutropenia Treatment Industry Trends Table 2. Chemotherapy-Induced Neutropenia Treatment Industry Drivers Table 3. Chemotherapy-Induced Neutropenia Treatment Industry Opportunities and Challenges Table 4. Chemotherapy-Induced Neutropenia Treatment Industry Restraints Table 5. Global Chemotherapy-Induced Neutropenia Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Chemotherapy-Induced Neutropenia Treatment Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Manufacturers Table 9. Global Chemotherapy-Induced Neutropenia Treatment Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Chemotherapy-Induced Neutropenia Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Chemotherapy-Induced Neutropenia Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Chemotherapy-Induced Neutropenia Treatment Manufacturers, Product Type & Application Table 13. Global Chemotherapy-Induced Neutropenia Treatment Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Chemotherapy-Induced Neutropenia Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Splenectomy Procedure Table 17. Major Manufacturers of Granulocyte Transfusion Table 18. Major Manufacturers of Antibiotic Therapy Table 19. Major Manufacturers of Colony-Stimulating Factor Therapy Table 20. Major Manufacturers of Others Table 21. Global Chemotherapy-Induced Neutropenia Treatment Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Chemotherapy-Induced Neutropenia Treatment Sales by Type (2021-2026) & (K Units) Table 23. Global Chemotherapy-Induced Neutropenia Treatment Sales by Type (2027-2032) & (K Units) Table 24. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Type (2021-2026) Table 25. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Type (2027-2032) Table 26. Global Chemotherapy-Induced Neutropenia Treatment Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Chemotherapy-Induced Neutropenia Treatment Revenue by Type (2021-2026) & (K Units) Table 28. Global Chemotherapy-Induced Neutropenia Treatment Revenue by Type (2027-2032) & (K Units) Table 29. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Ambulatory Surgical Center Table 32. Major Manufacturers of Hospitals Table 33. Major Manufacturers of Diagnostic Centers Table 34. Global Chemotherapy-Induced Neutropenia Treatment Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Chemotherapy-Induced Neutropenia Treatment Sales by Application (2021-2026) & (K Units) Table 36. Global Chemotherapy-Induced Neutropenia Treatment Sales by Application (2027-2032) & (K Units) Table 37. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Application (2021-2026) Table 38. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Application (2027-2032) Table 39. Global Chemotherapy-Induced Neutropenia Treatment Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Chemotherapy-Induced Neutropenia Treatment Revenue by Application (2021-2026) & (K Units) Table 41. Global Chemotherapy-Induced Neutropenia Treatment Revenue by Application (2027-2032) & (K Units) Table 42. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Application (2021-2026) Table 43. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Application (2027-2032) Table 44. Global Chemotherapy-Induced Neutropenia Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Chemotherapy-Induced Neutropenia Treatment Sales by Region (2021-2026) & (K Units) Table 46. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Region (2021-2026) Table 47. Global Chemotherapy-Induced Neutropenia Treatment Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Chemotherapy-Induced Neutropenia Treatment Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Chemotherapy-Induced Neutropenia Treatment Sales by Country (2021-2026) & (K Units) Table 51. North America Chemotherapy-Induced Neutropenia Treatment Sales by Country (2027-2032) & (K Units) Table 52. Europe Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Chemotherapy-Induced Neutropenia Treatment Sales by Country (2021-2026) & (K Units) Table 54. Europe Chemotherapy-Induced Neutropenia Treatment Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales by Country (2027-2032) & (K Units) Table 61. Global Chemotherapy-Induced Neutropenia Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Chemotherapy-Induced Neutropenia Treatment Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Chemotherapy-Induced Neutropenia Treatment Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Region (2021-2026) Table 65. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Region (2027-2032) Table 66. Teva Pharmaceuticals Industries Company Information Table 67. Teva Pharmaceuticals Industries Business Overview Table 68. Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia Treatment Product Portfolio Table 70. Teva Pharmaceuticals Industries Recent Development Table 71. Sanofi Company Information Table 72. Sanofi Business Overview Table 73. Sanofi Chemotherapy-Induced Neutropenia Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Sanofi Chemotherapy-Induced Neutropenia Treatment Product Portfolio Table 75. Sanofi Recent Development Table 76. Novartis AG Company Information Table 77. Novartis AG Business Overview Table 78. Novartis AG Chemotherapy-Induced Neutropenia Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Novartis AG Chemotherapy-Induced Neutropenia Treatment Product Portfolio Table 80. Novartis AG Recent Development Table 81. Baxter International Company Information Table 82. Baxter International Business Overview Table 83. Baxter International Chemotherapy-Induced Neutropenia Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Baxter International Chemotherapy-Induced Neutropenia Treatment Product Portfolio Table 85. Baxter International Recent Development Table 86. Amgen Company Information Table 87. Amgen Business Overview Table 88. Amgen Chemotherapy-Induced Neutropenia Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Amgen Chemotherapy-Induced Neutropenia Treatment Product Portfolio Table 90. Amgen Recent Development Table 91. Ligand Pharmaceuticals Company Information Table 92. Ligand Pharmaceuticals Business Overview Table 93. Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia Treatment Product Portfolio Table 95. Ligand Pharmaceuticals Recent Development Table 96. Dr. Reddy’s Laboratory Company Information Table 97. Dr. Reddy’s Laboratory Business Overview Table 98. Dr. Reddy’s Laboratory Chemotherapy-Induced Neutropenia Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Dr. Reddy’s Laboratory Chemotherapy-Induced Neutropenia Treatment Product Portfolio Table 100. Dr. Reddy’s Laboratory Recent Development Table 101. Biogenomics Limited Company Information Table 102. Biogenomics Limited Business Overview Table 103. Biogenomics Limited Chemotherapy-Induced Neutropenia Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Biogenomics Limited Chemotherapy-Induced Neutropenia Treatment Product Portfolio Table 105. Biogenomics Limited Recent Development Table 106. Apotex Company Information Table 107. Apotex Business Overview Table 108. Apotex Chemotherapy-Induced Neutropenia Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Apotex Chemotherapy-Induced Neutropenia Treatment Product Portfolio Table 110. Apotex Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Chemotherapy-Induced Neutropenia Treatment Distributors List Table 114. Chemotherapy-Induced Neutropenia Treatment Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Chemotherapy-Induced Neutropenia Treatment Product Image Figure 2. Global Chemotherapy-Induced Neutropenia Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chemotherapy-Induced Neutropenia Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Chemotherapy-Induced Neutropenia Treatment Sales (2021-2032) & (K Units) Figure 5. Global Chemotherapy-Induced Neutropenia Treatment Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Chemotherapy-Induced Neutropenia Treatment Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Splenectomy Procedure Image Figure 9. Granulocyte Transfusion Image Figure 10. Antibiotic Therapy Image Figure 11. Colony-Stimulating Factor Therapy Image Figure 12. Others Image Figure 13. Global Chemotherapy-Induced Neutropenia Treatment Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Type (2021-2032) Figure 16. Global Chemotherapy-Induced Neutropenia Treatment Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Type (2021-2032) Figure 19. Ambulatory Surgical Center Image Figure 20. Hospitals Image Figure 21. Diagnostic Centers Image Figure 22. Global Chemotherapy-Induced Neutropenia Treatment Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Application (2021-2032) Figure 25. Global Chemotherapy-Induced Neutropenia Treatment Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Application (2021-2032) Figure 28. North America Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Country (2021-2032) Figure 30. U.S. Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Country (2021-2032) Figure 35. Germany Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Country (2021-2032) Figure 42. China Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Country (2021-2032) Figure 50. Brazil Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Chemotherapy-Induced Neutropenia Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Chemotherapy-Induced Neutropenia Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Chemotherapy-Induced Neutropenia Treatment Revenue (2021-2032) & (US$ Million) Figure 61. North America Chemotherapy-Induced Neutropenia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Chemotherapy-Induced Neutropenia Treatment Revenue (2021-2032) & (US$ Million) Figure 63. Europe Chemotherapy-Induced Neutropenia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Chemotherapy-Induced Neutropenia Treatment Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Chemotherapy-Induced Neutropenia Treatment Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Splenectomy Procedure
  • Granulocyte Transfusion
  • Antibiotic Therapy
  • Colony-Stimulating Factor Therapy
  • Others
Applications
  • Ambulatory Surgical Center
  • Hospitals
  • Diagnostic Centers
Companies covered
  • Teva Pharmaceuticals Industries
  • Sanofi
  • Novartis AG
  • Baxter International
  • Amgen
  • Ligand Pharmaceuticals
  • Dr. Reddy’s Laboratory
  • Biogenomics Limited
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Chemotherapy-Induced Neutropenia Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Chemotherapy-Induced Neutropenia Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Chemotherapy-Induced Neutropenia Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Chemotherapy-Induced Neutropenia Treatment Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Chemotherapy-Induced Neutropenia Treatment Market Dynamics
  1. 2.1 Chemotherapy-Induced Neutropenia Treatment Industry Trends
  2. 2.2 Chemotherapy-Induced Neutropenia Treatment Industry Drivers
  3. 2.3 Chemotherapy-Induced Neutropenia Treatment Industry Opportunities and Challenges
  4. 2.4 Chemotherapy-Induced Neutropenia Treatment Industry Restraints
3 Chemotherapy-Induced Neutropenia Treatment Market by Manufacturers
  1. 3.1 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Chemotherapy-Induced Neutropenia Treatment Sales by Manufacturers (2021-2026)
  3. 3.3 Global Chemotherapy-Induced Neutropenia Treatment Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Chemotherapy-Induced Neutropenia Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chemotherapy-Induced Neutropenia Treatment Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Chemotherapy-Induced Neutropenia Treatment Manufacturers, Product Type & Application
  7. 3.7 Global Chemotherapy-Induced Neutropenia Treatment Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chemotherapy-Induced Neutropenia Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chemotherapy-Induced Neutropenia Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chemotherapy-Induced Neutropenia Treatment Tier 1, Tier 2, and Tier 3
4 Chemotherapy-Induced Neutropenia Treatment Market by Type
  1. 4.1 Chemotherapy-Induced Neutropenia Treatment Type Introduction
  2. 4.1.1 Splenectomy Procedure
  3. 4.1.2 Granulocyte Transfusion
  4. 4.1.3 Antibiotic Therapy
  5. 4.1.4 Colony-Stimulating Factor Therapy
  6. 4.1.5 Others
  7. 4.2 Global Chemotherapy-Induced Neutropenia Treatment Sales by Type
  8. 4.2.1 Global Chemotherapy-Induced Neutropenia Treatment Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Chemotherapy-Induced Neutropenia Treatment Sales by Type (2021-2032)
  10. 4.2.3 Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Type (2021-2032)
  11. 4.3 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Type
  12. 4.3.1 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Type (2021-2032)
  14. 4.3.3 Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Type (2021-2032)
5 Chemotherapy-Induced Neutropenia Treatment Market by Application
  1. 5.1 Chemotherapy-Induced Neutropenia Treatment Application Introduction
  2. 5.1.1 Ambulatory Surgical Center
  3. 5.1.2 Hospitals
  4. 5.1.3 Diagnostic Centers
  5. 5.2 Global Chemotherapy-Induced Neutropenia Treatment Sales by Application
  6. 5.2.1 Global Chemotherapy-Induced Neutropenia Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chemotherapy-Induced Neutropenia Treatment Sales by Application (2021-2032)
  8. 5.2.3 Global Chemotherapy-Induced Neutropenia Treatment Sales Market Share by Application (2021-2032)
  9. 5.3 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Application
  10. 5.3.1 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Application (2021-2032)
  12. 5.3.3 Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Application (2021-2032)
6 Global Chemotherapy-Induced Neutropenia Treatment Sales by Region
  1. 6.1 Global Chemotherapy-Induced Neutropenia Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chemotherapy-Induced Neutropenia Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Chemotherapy-Induced Neutropenia Treatment Sales by Region (2021-2026)
  4. 6.2.2 Global Chemotherapy-Induced Neutropenia Treatment Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Chemotherapy-Induced Neutropenia Treatment Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Chemotherapy-Induced Neutropenia Treatment Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Chemotherapy-Induced Neutropenia Treatment Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Region
  1. 7.1 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Region
  2. 7.1.1 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Region (2021-2026)
  4. 7.1.3 Global Chemotherapy-Induced Neutropenia Treatment Revenue by Region (2027-2032)
  5. 7.1.4 Global Chemotherapy-Induced Neutropenia Treatment Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Chemotherapy-Induced Neutropenia Treatment Revenue (2021-2032)
  8. 7.2.2 North America Chemotherapy-Induced Neutropenia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Chemotherapy-Induced Neutropenia Treatment Revenue (2021-2032)
  11. 7.3.2 Europe Chemotherapy-Induced Neutropenia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Chemotherapy-Induced Neutropenia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Chemotherapy-Induced Neutropenia Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceuticals Industries
  2. 8.1.1 Teva Pharmaceuticals Industries Company Information
  3. 8.1.2 Teva Pharmaceuticals Industries Business Overview
  4. 8.1.3 Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceuticals Industries Chemotherapy-Induced Neutropenia Treatment Product Portfolio
  6. 8.1.5 Teva Pharmaceuticals Industries Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Chemotherapy-Induced Neutropenia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Chemotherapy-Induced Neutropenia Treatment Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis AG
  14. 8.3.1 Novartis AG Company Information
  15. 8.3.2 Novartis AG Business Overview
  16. 8.3.3 Novartis AG Chemotherapy-Induced Neutropenia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis AG Chemotherapy-Induced Neutropenia Treatment Product Portfolio
  18. 8.3.5 Novartis AG Recent Developments
  19. 8.4 Baxter International
  20. 8.4.1 Baxter International Company Information
  21. 8.4.2 Baxter International Business Overview
  22. 8.4.3 Baxter International Chemotherapy-Induced Neutropenia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Baxter International Chemotherapy-Induced Neutropenia Treatment Product Portfolio
  24. 8.4.5 Baxter International Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen Chemotherapy-Induced Neutropenia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Amgen Chemotherapy-Induced Neutropenia Treatment Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 Ligand Pharmaceuticals
  32. 8.6.1 Ligand Pharmaceuticals Company Information
  33. 8.6.2 Ligand Pharmaceuticals Business Overview
  34. 8.6.3 Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ligand Pharmaceuticals Chemotherapy-Induced Neutropenia Treatment Product Portfolio
  36. 8.6.5 Ligand Pharmaceuticals Recent Developments
  37. 8.7 Dr. Reddy’s Laboratory
  38. 8.7.1 Dr. Reddy’s Laboratory Company Information
  39. 8.7.2 Dr. Reddy’s Laboratory Business Overview
  40. 8.7.3 Dr. Reddy’s Laboratory Chemotherapy-Induced Neutropenia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Dr. Reddy’s Laboratory Chemotherapy-Induced Neutropenia Treatment Product Portfolio
  42. 8.7.5 Dr. Reddy’s Laboratory Recent Developments
  43. 8.8 Biogenomics Limited
  44. 8.8.1 Biogenomics Limited Company Information
  45. 8.8.2 Biogenomics Limited Business Overview
  46. 8.8.3 Biogenomics Limited Chemotherapy-Induced Neutropenia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Biogenomics Limited Chemotherapy-Induced Neutropenia Treatment Product Portfolio
  48. 8.8.5 Biogenomics Limited Recent Developments
  49. 8.9 Apotex
  50. 8.9.1 Apotex Company Information
  51. 8.9.2 Apotex Business Overview
  52. 8.9.3 Apotex Chemotherapy-Induced Neutropenia Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Apotex Chemotherapy-Induced Neutropenia Treatment Product Portfolio
  54. 8.9.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chemotherapy-Induced Neutropenia Treatment Value Chain Analysis
  2. 9.1.1 Chemotherapy-Induced Neutropenia Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chemotherapy-Induced Neutropenia Treatment Production Mode & Process
  6. 9.2 Chemotherapy-Induced Neutropenia Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chemotherapy-Induced Neutropenia Treatment Distributors
  9. 9.2.3 Chemotherapy-Induced Neutropenia Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst